Follow the NKGen Biotech, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 2 June 2025 (Acquisition). Among the most active insiders: Song Paul Y.. Every trade is free.
12
Insider Decl.
n/a
Thresholds
€5m
8 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NKGen Biotech, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
45Σ signal
Buys €5mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
NKGen Biotech, Inc. is a biopharmaceutical company focused on developing NK cell-based therapies for cancer treatment. It is listed on NASDAQ under the ticker NK.